# Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

> **NCT02603068** · PHASE2 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Hypertension
- Pulmonary Fibrosis

## Interventions

- **DRUG:** Oral treprostinil

## Key facts

- **NCT ID:** NCT02603068
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-02
- **Primary completion:** 2018-04
- **Final completion:** 2018-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study design was inadequate and would not achieve study endpoints
- **Last updated:** 2016-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603068, "Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02603068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*